Navigation Links
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
Date:3/16/2008

otherapy were deemed eligible for consolidation treatment six to ten weeks after the sixth cycle with one course of Zevalin. Primary endpoints were complete response and hematological toxic effects and secondary endpoints were overall survival and progression-free survival.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with Rituximab-refractory NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit http://www.zevalin.com for more information.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
2. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
3. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
4. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
5. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
6. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
7. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
8. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
9. First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
10. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
11. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 "Copay ... inflate sales of brand drugs among patients with ... according to a new report  from the ... of the Inspector General (OIG). Federal anti-kickback laws prohibit ... that are subsidized by the federal government. ...
(Date:9/19/2014)... Today, iHealth Lab Inc. announced it has secured ... its first institutional round of funding. The strategic investment ... accelerate growth and innovation, and invest in additional sales ... Ventures will join iHealth,s board of directors, bringing added ... "We are very pleased to have Xiaomi ...
(Date:9/19/2014)... LUBBOCK, Texas , Sept. 19, 2014 Kiromic, ... today the addition of Kent Hance , the former ... vice chairman. Hance retired as chancellor in July 2014, after ... pleased to announce that Kent Hance , the most ... joined the Kiromic team not only as an investor, but ...
Breaking Medicine Technology:PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2
... Feb. 20, 2011 NxStage® Medical, Inc. ... innovative dialysis products, today announced the latest interim results ... in overall quality of life benefits, significant improvement in ... Legs Syndrome (RLS) symptoms experienced by patients after 12 ...
... One year to the day of its introduction, the ... to its official company launch.  "Starting a new company takes ... about the industry and our place in it and now ... healthcare." Dr. McCord is no stranger to healthcare. ...
Cached Medicine Technology:New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period 2New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period 3New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period 4
(Date:9/21/2014)... York (PRWEB) September 21, 2014 ... their Risk Management Portal designed for Diocesan risks. ... the intent to support effective risk management and ... to go live coinciding with Waldorf’s exhibition at ... 2014. , These applications were developed in collaboration ...
(Date:9/21/2014)... Texas (PRWEB) September 22, 2014 ... the past decade, as it has become saturated ... beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and ... also been facing increasing generic competition. However, the ... once-daily ICS and ICS/LABA therapies delivered by the ...
(Date:9/21/2014)... "I want to help people who are having ... money for chiropractors," said an inventor from St. Amat, ... for myself." , The Stretch is a device that ... and align the spine properly. It improves flexibility and ... nerves. Compact and easy to use, it's ideal for ...
(Date:9/21/2014)... 2014 (HealthDay News) -- Young women starting college understand ... foods they should eat. But they aren,t confident they ... to a new study. The study involved ... Illinois,s Peer Education Exercising and Eating Right program. The ... choose to eat if they were very busy with ...
(Date:9/21/2014)... 2014 Originally approved by the ... Flovent (fluticasone propionate) is a synthetic ICS therapy ... the maintenance treatment of asthma prophylactically in children ... formulations, Diskus and HFA, which received the FDA ... ingredient, fluticasone propionate, can bind to glucocorticoid receptors ...
Breaking Medicine News(10 mins):Health News:Waldorf Risk Solutions Releases New Risk Management Portal 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News: College Women Can Use Food Strategies, Study Finds 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4
... WellPoint, Inc. (NYSE: WLP ) announced ... New York Attorney General regarding the manner in which ... terms of the Agreement with the Attorney General, WellPoint ... database, which it uses in determining out-of-network reimbursement for ...
... RI Researchers at Rhode Island Hospital have completed ... control measures during a possible flu pandemic. Their study ... from individuals showing no symptoms (asymptomatic) or from individuals ... The researchers call on the scientific community to ...
... LOUISVILLE, Ky., Feb. 18 Almost Family, Inc. (Nasdaq: ... nursing services, announced today that it will be added to ... on Friday, February 20, 2009.William Yarmuth, President and CEO of ... included in the S&P SmallCap 600 Index, as it adds ...
... Taking Control of Your Diabetes,(TCOYD) announced findings ... firm Yankelovich that found that more than one ... that excess weight has a positive effect on,the ... often contributes,to the development of diabetes, complicates proper ...
... love their meat. Whether it,s rib eyes, pork chops or ... this country that more than 85 billion pounds of meat ... About a quarter of U.S. beef and pork is exported ... now the world,s largest consumer of meat, in Mexico, meat ...
... Spanish . , A team of specialists ... of genetic variants that have greater resistance to a specific ... some child patients affected by osteosarcoma. The team investigated the ... therapeutic treatment in the future. , In concrete, the research ...
Cached Medicine News:Health News:WellPoint Joins New York Attorney General in Creation of New Independent Database for Out-of-Network Reimbursement 2Health News:Study calls for increased research in flu transmission to prepare for pandemic flu outbreak 2Health News:Almost Family to be Added to the S&P SmallCap 600 Index 2Health News:One in Five Augustans With Type 2 Diabetes Mistakenly Believe That Being Obese or Overweight Can Positively Impact Their Disease 2Health News:One in Five Augustans With Type 2 Diabetes Mistakenly Believe That Being Obese or Overweight Can Positively Impact Their Disease 3Health News:American Veterinary Medical Association: Weaving a Web for Food Safety 2Health News:Research increases possibilities of personalizing treatment of infant osteosarcoma 2Health News:Research increases possibilities of personalizing treatment of infant osteosarcoma 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: